

Xiao-Li Wei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6837951/publications.pdf>

Version: 2024-02-01

42
papers

3,625
citations

279798

23
h-index

276875

41
g-index

42
all docs

42
docs citations

42
times ranked

4663
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy. <i>JAMA Network Open</i> , 2022, 5, e220587.	5.9	23
2	Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. <i>Cancer Cell</i> , 2022, 40, 277-288.e3.	16.8	177
3	Optimizing Chemotherapy of Pancreatic Acinar Cell Carcinoma: Our Experiences and Pooled Analysis of Literature. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210901.	1.3	4
4	Current status and advances of immunotherapy in nasopharyngeal carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962.	3.2	23
5	Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. <i>Gastroenterology Report</i> , 2021, 9, 560-570.	1.3	10
6	Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592198899.	3.2	17
7	Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel. <i>Journal of Medical Genetics</i> , 2021, , jmedgenet-2020-107230.	3.2	11
8	Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). <i>Journal of Clinical Oncology</i> , 2021, 39, 704-712.	1.6	156
9	A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. <i>Leukemia</i> , 2021, 35, 3212-3222.	7.2	15
10	Development and Validation of a Prognostic Classifier Based on Lipid Metabolism-Related Genes in Gastric Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 691143.	3.5	22
11	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1536-1543.	30.7	197
12	Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. <i>Cell Reports Medicine</i> , 2021, 2, 100383.	6.5	49
13	The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. <i>Oncolmmunology</i> , 2021, 10, 1938381.	4.6	10
14	PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. <i>American Journal of Cancer Research</i> , 2021, 11, 5006-5015.	1.4	0
15	Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients. <i>International Journal of Cancer</i> , 2020, 146, 272-280.	5.1	41
16	Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells. <i>Theranostics</i> , 2020, 10, 498-515.	10.0	68
17	Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093743.	3.2	16
18	Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 563407.	2.8	5

#	ARTICLE	IF	CITATIONS
19	PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 475.	4.4	23
20	Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. <i>Clinical and Translational Medicine</i> , 2020, 10, 353-362.	4.0	13
21	A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. <i>Cancer Communications</i> , 2020, 40, 345-354.	9.2	30
22	Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. <i>Cancer Communications</i> , 2019, 39, 1-12.	9.2	1,177
23	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. <i>Cancer Communications</i> , 2019, 39, 1-31.	9.2	418
24	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. <i>International Journal of Cancer</i> , 2019, 144, 2161-2168.	5.1	34
25	A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients. <i>Cell Death Discovery</i> , 2018, 4, 116.	4.7	16
26	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. <i>Journal of Cancer</i> , 2018, 9, 4325-4333.	2.5	16
27	Hepatitis B virus infection is associated with younger median age at diagnosis and death in cancers. <i>International Journal of Cancer</i> , 2017, 141, 152-159.	5.1	38
28	Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. <i>Theranostics</i> , 2017, 7, 4836-4849.	10.0	265
29	Clinical Significance of Preoperative Albumin and Globulin Ratio in Patients with Gastric Cancer Undergoing Treatment. <i>BioMed Research International</i> , 2017, 2017, 1-8.	1.9	37
30	>Fc&gamma;RII and >III polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5065-5076.	2.0	11
31	Redox Regulation of Stem-like Cells Through the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications. <i>Theranostics</i> , 2016, 6, 1160-1175.	10.0	75
32	The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 1879-1887.	1.8	33
33	The clinicopathologic relevance and prognostic value of tumor deposits and the applicability of N1c category in rectal cancer with preoperative radiotherapy. <i>Oncotarget</i> , 2016, 7, 75094-75103.	1.8	23
34	A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. <i>BMC Cancer</i> , 2015, 15, 350.	2.6	126
35	Patients with Old Age or Proximal Tumors Benefit from Metabolic Syndrome in Early Stage Gastric Cancer. <i>PLoS ONE</i> , 2014, 9, e89965.	2.5	17
36	Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 18404.	3.3	38

#	ARTICLE	IF	CITATIONS
37	The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 249.	4.4	34
38	The Role of Non-Curative Surgery in Incurable, Asymptomatic Advanced Gastric Cancer. <i>PLoS ONE</i> , 2013, 8, e83921.	2.5	27
39	ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. <i>International Journal of Cancer</i> , 2012, 131, 461-468.	5.1	102
40	DNA polymerase β protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. <i>Journal of Translational Medicine</i> , 2010, 8, 126.	4.4	53
41	Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2008, 8, 115.	2.6	56
42	High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. <i>Cancer</i> , 2007, 109, 1360-1364.	4.1	119